TMCI Stock Overview
A medical technology company, designs, manufactures, and markets medical devices in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Treace Medical Concepts, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.82 |
| 52 Week High | US$10.79 |
| 52 Week Low | US$4.29 |
| Beta | 0.80 |
| 1 Month Change | 1.26% |
| 3 Month Change | -33.33% |
| 1 Year Change | 55.71% |
| 3 Year Change | -53.19% |
| 5 Year Change | n/a |
| Change since IPO | -73.29% |
Recent News & Updates
Recent updates
Treace Medical Concepts, Inc. (NASDAQ:TMCI) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
May 11
Treace Medical Concepts: No Solid Footing
Apr 07
New Bunion Treatments Will Open Broader Market Opportunities
Mar 27 Innovative products and expanded portfolio aim to penetrate the U.S. bunion market and enhance revenue through increased surgeon adoption and market appeal.Treace Medical Concepts, Inc. (NASDAQ:TMCI) Stock Rockets 26% But Many Are Still Ignoring The Company
Jan 18Further Upside For Treace Medical Concepts, Inc. (NASDAQ:TMCI) Shares Could Introduce Price Risks After 84% Bounce
Dec 03Is Treace Medical Concepts (NASDAQ:TMCI) Using Debt In A Risky Way?
Oct 26Treace Medical Concepts, Inc. (NASDAQ:TMCI) Screens Well But There Might Be A Catch
Aug 02Treace Medical Concepts (NASDAQ:TMCI) Has Debt But No Earnings; Should You Worry?
Jun 28Treace Medical Concepts: Facing Increasing Competitive Pressure
Jun 14Market Still Lacking Some Conviction On Treace Medical Concepts, Inc. (NASDAQ:TMCI)
Apr 05Does Treace Medical Concepts (NASDAQ:TMCI) Have A Healthy Balance Sheet?
Feb 09Why Investors Shouldn't Be Surprised By Treace Medical Concepts, Inc.'s (NASDAQ:TMCI) 31% Share Price Surge
Jan 04Market Cool On Treace Medical Concepts, Inc.'s (NASDAQ:TMCI) Revenues Pushing Shares 46% Lower
Nov 11Shareholder Returns
| TMCI | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -6.1% | 0.09% | -0.3% |
| 1Y | 55.7% | 7.7% | 8.1% |
Return vs Industry: TMCI exceeded the US Medical Equipment industry which returned 7.5% over the past year.
Return vs Market: TMCI exceeded the US Market which returned 8% over the past year.
Price Volatility
| TMCI volatility | |
|---|---|
| TMCI Average Weekly Movement | 6.8% |
| Medical Equipment Industry Average Movement | 9.7% |
| Market Average Movement | 8.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 4.2% |
Stable Share Price: TMCI has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: TMCI's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 477 | John Treace | www.treace.com |
Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to correct three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision.
Treace Medical Concepts, Inc. Fundamentals Summary
| TMCI fundamental statistics | |
|---|---|
| Market cap | US$429.01m |
| Earnings (TTM) | -US$52.99m |
| Revenue (TTM) | US$210.82m |
2.0x
P/S Ratio-8.1x
P/E RatioIs TMCI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TMCI income statement (TTM) | |
|---|---|
| Revenue | US$210.82m |
| Cost of Revenue | US$41.64m |
| Gross Profit | US$169.18m |
| Other Expenses | US$222.17m |
| Earnings | -US$52.99m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.84 |
| Gross Margin | 80.25% |
| Net Profit Margin | -25.13% |
| Debt/Equity Ratio | 50.7% |
How did TMCI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/11 15:58 |
| End of Day Share Price | 2025/05/09 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Treace Medical Concepts, Inc. is covered by 10 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Gorman | BTIG |
| Lilia-Celine Lozada | J.P. Morgan |
| Robert Marcus | J.P. Morgan |